In two independent cohorts, e-Lung automated biomarkers are highly prognostic, outperforming FVC confirming previous findings in patients with IPF. Clinical trial endpoints combining e-Lung imaging biomarkers with FVC may improve definition of treatment response in ILD; this is being explored in prospective clinical trials.
Collaborating and Innovating with our Partners
Winner
Reddot Award: Design Concept 2025
Winner
Top Science Award at AHA Health Tech Competition 2025
Winner
Best Established MedTech Company 2025
Winner
Life Sciences & Health Tech Company of the Year
Winner
HealthTech Company of the Year 2024
Winner
Most Transformative HealthTech Company 2024
Winner
Life Sciences & HealthTech Company of the Year 2023
Winner
Innovative Tech Company
Winner
Best Established MedTech Company 2023